<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905992</url>
  </required_header>
  <id_info>
    <org_study_id>HS_nonInferiority</org_study_id>
    <nct_id>NCT04905992</nct_id>
  </id_info>
  <brief_title>Is a Single Daily Session Combining HS + Physio Sufficient to Obtain Long-term Clinical Benefits in Bronchiectasis?</brief_title>
  <official_title>Is a Single Daily Session Combining Hypertonic Saline Nebulisation and Airway Clearance Techniques Sufficient to Obtain Long-term Clinical Benefits in People With Bronchiectasis? A Randomised Non-inferiority Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clínico Universitario Lozano Blesa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad San Jorge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clínico Universitario Lozano Blesa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will aim to find out whether a home treatment in people with bronchiectasis&#xD;
      consisting of a single daily session to facilitate expectoration (combining nebulization of&#xD;
      hypertonic saline (HS) at 6% followed by airway clearance techniques) is at least as&#xD;
      effective as performing two sessions per day following the same process in each of the&#xD;
      sessions, during a period of 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-inferiority randomised clinical trial (single-blind) will be conducted. At least 50&#xD;
      participants will be recruited from the outpatient clinics of the Hospital Clinic in&#xD;
      Barcelona and the Clinical University Hospital in Zaragoza. The experimental group will&#xD;
      nebulize once/day the hypertonic saline (HS) solution followed by airway clearance exercises&#xD;
      (15 min) for 6 months. The control group will follow the same procedure, but the frequency of&#xD;
      the sessions will be twice a day (reference as usual clinical practice). The main study&#xD;
      outcomes will be: (1) cough severity (primary endpoint), symptoms and quality of life; (2)&#xD;
      functional exercise capacity; (3) time to first exacerbation and total number of&#xD;
      exacerbations; (4) indirect measures of mucociliary transport (rheology and concentration of&#xD;
      solids in sputum samples); (5) inflammatory parameters; (5) tolerance, safety and adherence&#xD;
      to treatment. Measurements will be taken at baseline (prior to randomization), at 1 month, 3&#xD;
      months, and 6 months. Finally, hypothesis testing will be performed using a linear mixed&#xD;
      model (2x3) of repeated measures, establishing a priori a margin of non-inferiority.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A non-inferiority randomized clinical trial (single-blinded assessor).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The assessors in charge of the measures will be blind to the group assignment of participants until the study has been completed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of coughing on quality of life</measure>
    <time_frame>6 months after starting the intervention</time_frame>
    <description>The Leicester Cough Questionnaire (LCQ) will be used to assess the daily cough impact</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of coughing on quality of life</measure>
    <time_frame>Baseline point, 1 month and 3 months after starting the intervention</time_frame>
    <description>The Leicester Cough Questionnaire (LCQ) will be used to assess the daily cough impact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific quality of life questionnaire</measure>
    <time_frame>Baseline point, 1 month, 3 months and 6 months after starting the intervention</time_frame>
    <description>The Quality of life of Bronchiectasis (QoL-B) questionnaire will be used to evaluate the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific symptoms questionnaire</measure>
    <time_frame>Baseline point, 1 month, 3 months and 6 months after starting the intervention</time_frame>
    <description>The Bronchiectasis Impact Measure (BIM) outcome measure will be used to analyse the symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>Baseline point, 1 month, 3 months and 6 months after starting the intervention</time_frame>
    <description>The sit to stand test (1 minute) will be used to assess the exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>Baseline point</time_frame>
    <description>The six minute walk distance (6MWT) will be used to assess the exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>From baseline point to the end of the intervention (6 months)</time_frame>
    <description>The number of exacerbations, the severity of exacerbations (hospital admission) and the time to the first exacerbation will be recorded prospectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biophysical properties of spontaneous sputum samples</measure>
    <time_frame>Baseline point, 1 month, 3 months, 6 months</time_frame>
    <description>Spontaneous sputum samples will be collected to analyse the main biophysical markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation markers (airway inflammation and systemic inflammation)</measure>
    <time_frame>Baseline point, 1 month, 3 months, 6 months</time_frame>
    <description>Blood and salivary samples will be collected to analyse the main inflammatory markers (neutrophil elastase, cytokines, peptides)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lung Function</measure>
    <time_frame>Baseline point, 1 month, 3 months, 6 months</time_frame>
    <description>Forced spirometry (forced expiratory volume in 1 second [FEV1] and forced vital capacity [FVC]) will be perform for safety analysis following the American Thoracic Society / European Respiratory Society guidelines</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events during sessions</measure>
    <time_frame>Baseline point, 1 month, 3 months, 6 months</time_frame>
    <description>Adverse events during nebulisation period will be recorded using a Likert scale and participants will also complete the Self-Reported Medication Scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bronchiectasis</condition>
  <condition>Airway Clearance Impairment</condition>
  <arm_group>
    <arm_group_label>Single daily session (Hypertonic saline + airway clearance techniques)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will perform a daily session at home including nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily session (Hypertonic saline + airway clearance techniques)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will perform two daily sessions at home involving nebulisation of 5 mL of hypertonic saline (at 6%) followed by 15 min of airway clearance techniques (oscillating positive expiratory pressure therapy) for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypertonic saline at 6%</intervention_name>
    <description>Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.</description>
    <arm_group_label>Single daily session (Hypertonic saline + airway clearance techniques)</arm_group_label>
    <arm_group_label>Twice daily session (Hypertonic saline + airway clearance techniques)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Airway clearance techniques (oscillating positive expiratory pressure therapy)</intervention_name>
    <description>Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home</description>
    <arm_group_label>Single daily session (Hypertonic saline + airway clearance techniques)</arm_group_label>
    <arm_group_label>Twice daily session (Hypertonic saline + airway clearance techniques)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years or older&#xD;
&#xD;
          2. a total score less than 16 on the Leicester Cough Questionnaire&#xD;
&#xD;
          3. chronic daily expectoration over at least 3 months&#xD;
&#xD;
          4. being in a period of clinical stability during the previous 4 weeks&#xD;
&#xD;
          5. presenting a forced expiratory volume in 1 second (FEV1) value greater than 40% of&#xD;
             predicted or &gt;1 L&#xD;
&#xD;
          6. obtaining informed consent.&#xD;
&#xD;
        In addition, all participants will have had to satisfactorily pass the tolerability tests,&#xD;
        which will be performed twice: i) on the first day; ii) and the following week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. having received nebulised mucoactive treatment during the previous year&#xD;
&#xD;
          2. frequent haemoptysis (≥ 2 times/month)&#xD;
&#xD;
          3. diagnosis or suspicion of cystic fibrosis by genetic study or sweat test&#xD;
&#xD;
          4. being under active treatment for nontuberculous mycobacteria (NTM)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria Alcaraz-Serrano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beatriz Herrero-Cortina</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatriz Herrero-Cortina</last_name>
    <phone>34653051357</phone>
    <email>Beafisiorespi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatriz Herrero Cortina</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Beatriz Herrero-Cortina</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Herrero-Cortina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario Lozano Blesa</investigator_affiliation>
    <investigator_full_name>Beatriz Herrero-Cortina</investigator_full_name>
    <investigator_title>PhD Beatriz Herrero Cortina</investigator_title>
  </responsible_party>
  <keyword>Airway clearance techniques</keyword>
  <keyword>Hypertonic saline</keyword>
  <keyword>Hyperosmolar agents</keyword>
  <keyword>Oscillating positive expiratory pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

